Abstract | PURPOSE: EXPERIMENTAL DESIGN: Eighteen patients with melanoma were vaccinated s.c. in the adjuvant setting on weeks 0, 1, 2, 3, 10, and 24. Groups of 6 patients were entered at three dose levels (3, 10, or 30 micro g) of GD2 lactone (GD2L) in vaccines containing GD2L-KLH plus the immunological adjuvant QS-21. Blood was drawn at regular intervals to assess the antibody response. RESULTS: The vaccine was well tolerated. The majority of patients in all three dose levels produced anti-GD2 antibodies detectable by ELISA assay. Specificity for GD2 was also confirmed by immune thin-layer chromatography. Although there was no statistical difference in terms of titers between the three groups, patients at the 30- micro g dose level had higher titers and longer lasting antibody responses overall by ELISA (median IgM/ IgG peak titer 1:640/1:80) and generated the strongest cell surface reactivity by fluorescence-activated cell sorting (median IgM peak percentage positive cells/mean fluorescence intensity for pre- and postvaccination sera is 10%/63 and 70%/135). Patients vaccinated with the 30- micro g GD2 dose also had the most potent complement dependent cytotoxicity using human complement, with 5 of 6 patients showing strong cell surface reactivity by fluorescence-activated cell sorting and >30% cytotoxicity by chromium release with a serum dilution of 1/100. CONCLUSIONS:
|
Authors | Govind Ragupathi, Philip O Livingston, Chandra Hood, John Gathuru, Susan E Krown, Paul B Chapman, Jedd D Wolchok, Linda J Williams, Roberta C Oldfield, Wen-Jen Hwu |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 9
Issue 14
Pg. 5214-20
(Nov 01 2003)
ISSN: 1078-0432 [Print] United States |
PMID | 14614001
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Adjuvants, Immunologic
- Cancer Vaccines
- Gangliosides
- Immunoglobulin G
- Immunoglobulin M
- Lactones
- Saponins
- Vaccines, Conjugate
- saponin QA-21V1
- ganglioside, GD2
- Hemocyanins
- keyhole-limpet hemocyanin
|
Topics |
- Adjuvants, Immunologic
- Antibody Formation
- Antibody Specificity
- Antibody-Dependent Cell Cytotoxicity
- Cancer Vaccines
(therapeutic use)
- Enzyme-Linked Immunosorbent Assay
- Gangliosides
(immunology)
- Hemocyanins
(immunology)
- Humans
- Immunoglobulin G
(immunology)
- Immunoglobulin M
(immunology)
- Lactones
(immunology, metabolism)
- Melanoma
(immunology, pathology, therapy)
- Saponins
(immunology, therapeutic use)
- Skin Neoplasms
(immunology, secondary, therapy)
- Vaccination
- Vaccines, Conjugate
(therapeutic use)
|